JACKSONVILLE, Fla., Oct. 7, 2005 (PRIMEZONE) -- Phlo Corporation (Pink Sheets:PHLC) ("Phlo") announced today that one of its affiliates (the "Company") has commenced initial sales to colleges and universities of its AQUIS(tm) Rapid Response Rehydration product line. The Athletic Department of Shepherd University, located in Shepherdstown, West Virginia, has recently placed its initial order for AQUIS(tm) Rapid Response Rehydration products. Shepherd offers a full range of men's and women's sports and competes in Division II of the NCAA and the West Virginia Intercollegiate Athletic Conference. Shepherd University won the President's Cup for all-around athletic excellence for the 2004-2005 season.
AQUIS(tm) Rapid Response Rehydration solutions are based on a patent-pending MEDS (Micro-Encapsulation Delivery System) technology, which allows for immediate absorption of the electrolyte payload into the bloodstream, beginning through the mucous membranes of the mouth. This micro-encapsulation of the electrolytes allows AQUIS(tm) to taste good (no salty taste), encouraging consumption prior to the point of dehydration.
In the future, the Company plans to announce further developments on the sales front, including purchases of AQUIS(tm) by additional colleges and universities as such purchases occur.
Additionally, MadLax Sports, one of the nation's top lacrosse stores, continues to purchase AQUIS(tm) products for resale to its customers in its three stores (located in McLean and Alexandria, Virginia and Olney, Maryland) and through its website. MadLax can be reached by telephone (toll-free) at 1-877-2-MADLAX or on the Internet at www.madlax.com.
Phlo also announced today that on October 5, 2005, it filed with the Securities and Exchange Commission its Form 10-QSB for the fiscal quarter ended September 30, 2004. Phlo is continuing its efforts to become completely current in its filings and believes that it will accomplish that goal in the very near future. However, Phlo cannot make any assurances with respect to the exact dates upon which such filings will be made due to factors normally associated with such a process, which are not under the control of Phlo.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patents-pending biotechnologies, which are sold on a commercial basis to governmental and institutional purchasers and to high volume chain stores, such as supermarkets and drug and convenience stores. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.